Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $2,435 | $5,900 | $12,106 | $29,214 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $1,610 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $222 | $151 | $168 | $173 |
| Total Curr. Assets | $2,988 | $6,520 | $14,520 | $30,164 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $8 |
| Goodwill | $0 | $0 | $0 | $8,866 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $1,610 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $35 | $67 | $131 | $186 |
| Total NC Assets | $35 | $67 | $131 | $10,670 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $3,023 | $6,587 | $14,651 | $40,834 |
| Liabilities | – | – | – | – |
| Payables | $937 | $603 | $2,858 | $1,543 |
| Short-Term Debt | $222 | $290 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $0 | $0 | $0 |
| Total Curr. Liab. | $1,511 | $1,299 | $4,266 | $2,111 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,511 | $1,299 | $4,266 | $2,111 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $5 |
| Retained Earnings | -$81,924 | -$76,348 | -$63,805 | -$32,197 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $1,512 | $5,287 | $10,385 | $38,723 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $3,023 | $6,587 | $14,651 | $40,834 |
| Net Debt | -$2,213 | -$5,610 | -$12,106 | -$29,214 |